{"id":62131,"date":"2026-04-01T23:35:28","date_gmt":"2026-04-01T15:35:28","guid":{"rendered":"https:\/\/flcube.com\/?p=62131"},"modified":"2026-04-01T23:35:29","modified_gmt":"2026-04-01T15:35:29","slug":"sirius-therapeutics-files-hong-kong-ipo-application-with-sirna-pipeline-targeting-coagulation-and-cardiometabolic-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62131","title":{"rendered":"Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases"},"content":{"rendered":"\n<p><strong>Sirius Therapeutics<\/strong>, a clinical-stage biotechnology company founded in 2021, announced it has submitted its <strong>listing application to the Hong Kong Stock Exchange<\/strong> for an <strong>initial public offering (IPO)<\/strong>, advancing its pipeline of <strong>siRNA therapies<\/strong> targeting coagulation disorders, cardiometabolic diseases, and obesity.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-company-profile\">Company Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Founded<\/strong><\/td><td>2021<\/td><\/tr><tr><td><strong>Stage<\/strong><\/td><td>Global clinical-stage biotechnology<\/td><\/tr><tr><td><strong>Therapeutic Focus<\/strong><\/td><td>siRNA therapies for coagulation disorders, cardiometabolic diseases, and obesity<\/td><\/tr><tr><td><strong>IPO Status<\/strong><\/td><td>Hong Kong Stock Exchange listing application submitted<\/td><\/tr><tr><td><strong>Pipeline Size<\/strong><\/td><td>21 programs in development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-lead-programs-portfolio\">Lead Programs Portfolio<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-srsd107-factor-xi-targeting-sirna\">SRSD107 \u2013 Factor XI-Targeting siRNA<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target<\/strong>: Factor XI (coagulation pathway)<\/li>\n\n\n\n<li><strong>Stage<\/strong>: Phase II multi-regional clinical trials<\/li>\n\n\n\n<li><strong>Geographies<\/strong>: Europe and China (additional Phase II study in China)<\/li>\n\n\n\n<li><strong>Partnership<\/strong>: Global co-development and commercialization collaboration with <strong>CRISPR Therapeutics<\/strong> (Nasdaq: CRSP)<\/li>\n\n\n\n<li><strong>Indication<\/strong>: Coagulation disorders<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-srsd216-lp-a-targeting-sirna\">SRSD216 \u2013 Lp(a)-Targeting siRNA<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target<\/strong>: Lipoprotein(a) [Lp(a)]<\/li>\n\n\n\n<li><strong>Stage<\/strong>: Multi-regional Phase IIa trial<\/li>\n\n\n\n<li><strong>Geographies<\/strong>: China and United States<\/li>\n\n\n\n<li><strong>Differentiation<\/strong>: Novel approach to cardiovascular risk reduction<\/li>\n\n\n\n<li><strong>Indication<\/strong>: Cardiometabolic diseases<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-srsd384-inhbe-targeting-sirna\">SRSD384 \u2013 INHBE-Targeting siRNA<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target<\/strong>: INHBE (inhibin beta E subunit)<\/li>\n\n\n\n<li><strong>Stage<\/strong>: Preclinical; progressing toward IND filing<\/li>\n\n\n\n<li><strong>Data Status<\/strong>: Positive preclinical results reported<\/li>\n\n\n\n<li><strong>Indication<\/strong>: Obesity<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-partnership-crispr-therapeutics\">Strategic Partnership \u2013 CRISPR Therapeutics<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Collaboration Type<\/strong>: Global co-development and commercialization<\/li>\n\n\n\n<li><strong>Asset<\/strong>: SRSD107 (Factor XI-targeting siRNA)<\/li>\n\n\n\n<li><strong>Partner<\/strong>: CRISPR Therapeutics (Nasdaq: CRSP)<\/li>\n\n\n\n<li><strong>Strategic Value<\/strong>: Leverages CRISPR&#8217;s global infrastructure and expertise<\/li>\n\n\n\n<li><strong>Financial Structure<\/strong>: Terms not disclosed; likely includes upfront, milestones, and royalties<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-analysis\">Market Opportunity Analysis<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-sirna-therapeutics-landscape\">siRNA Therapeutics Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology Validation<\/strong>: siRNA platform proven with multiple approved products (e.g., inclisiran, givosiran)<\/li>\n\n\n\n<li><strong>Dosing Advantage<\/strong>: Infrequent subcutaneous administration improves patient compliance<\/li>\n\n\n\n<li><strong>Target Specificity<\/strong>: High specificity reduces off-target effects<\/li>\n\n\n\n<li><strong>Market Growth<\/strong>: Global siRNA therapeutics market projected to exceed $10 billion by 2030<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-therapeutic-areas\">Therapeutic Areas<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Coagulation Disorders<\/strong>: Factor XI inhibition offers anticoagulation without bleeding risk<\/li>\n\n\n\n<li><strong>Cardiometabolic<\/strong>: Lp(a) represents emerging high-value cardiovascular target<\/li>\n\n\n\n<li><strong>Obesity<\/strong>: Massive market opportunity with limited effective long-term treatments<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ipo-strategic-rationale\">IPO Strategic Rationale<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-capital-requirements\">Capital Requirements<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical Development<\/strong>: Funding needed for global Phase II\/III trials across multiple programs<\/li>\n\n\n\n<li><strong>Manufacturing Scale-up<\/strong>: Investment required for GMP manufacturing capacity<\/li>\n\n\n\n<li><strong>Commercial Infrastructure<\/strong>: Building capabilities for potential product launches<\/li>\n\n\n\n<li><strong>Pipeline Expansion<\/strong>: Resources for advancing additional preclinical candidates<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-market-timing\">Market Timing<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Hong Kong Biotech Market<\/strong>: Favorable environment for innovative biotech IPOs<\/li>\n\n\n\n<li><strong>siRNA Momentum<\/strong>: Strong investor interest in RNA-targeting technologies<\/li>\n\n\n\n<li><strong>Global Expansion<\/strong>: Public listing supports international development strategy<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-positioning\">Competitive Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology Platform<\/strong>: Proprietary siRNA delivery and optimization capabilities<\/li>\n\n\n\n<li><strong>Pipeline Breadth<\/strong>: 21 programs provide diversification across therapeutic areas<\/li>\n\n\n\n<li><strong>Global Strategy<\/strong>: Multi-regional trials position for worldwide regulatory submissions<\/li>\n\n\n\n<li><strong>Partnership Leverage<\/strong>: CRISPR collaboration enhances credibility and resources<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding IPO plans, clinical development, and partnership arrangements. Actual results may differ due to risks including regulatory approvals, clinical trial outcomes, and market conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/sehk26033104397_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of sehk26033104397_c.\"><\/object><a id=\"wp-block-file--media-19a3abd8-7c2d-4cbd-8339-2852c236c0f4\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/sehk26033104397_c.pdf\">sehk26033104397_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/sehk26033104397_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-19a3abd8-7c2d-4cbd-8339-2852c236c0f4\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sirius Therapeutics, a clinical-stage biotechnology company founded in 2021, announced it has submitted its listing&#8230;<\/p>\n","protected":false},"author":1,"featured_media":62133,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[72,64,1962],"class_list":["post-62131","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-ipo","tag-rnai-aso","tag-sirius-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sirius Therapeutics, a clinical-stage biotechnology company founded in 2021, announced it has submitted its listing application to the Hong Kong Stock Exchange for an initial public offering (IPO), advancing its pipeline of siRNA therapies targeting coagulation disorders, cardiometabolic diseases, and obesity.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62131\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases\" \/>\n<meta property=\"og:description\" content=\"Sirius Therapeutics, a clinical-stage biotechnology company founded in 2021, announced it has submitted its listing application to the Hong Kong Stock Exchange for an initial public offering (IPO), advancing its pipeline of siRNA therapies targeting coagulation disorders, cardiometabolic diseases, and obesity.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62131\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-01T15:35:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-01T15:35:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0105.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62131#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62131\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases\",\"datePublished\":\"2026-04-01T15:35:28+00:00\",\"dateModified\":\"2026-04-01T15:35:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62131\"},\"wordCount\":442,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62131#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0105.webp\",\"keywords\":[\"IPO\",\"RNAi \\\/ ASO\",\"Sirius Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62131#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62131\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62131\",\"name\":\"Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62131#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62131#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0105.webp\",\"datePublished\":\"2026-04-01T15:35:28+00:00\",\"dateModified\":\"2026-04-01T15:35:29+00:00\",\"description\":\"Sirius Therapeutics, a clinical-stage biotechnology company founded in 2021, announced it has submitted its listing application to the Hong Kong Stock Exchange for an initial public offering (IPO), advancing its pipeline of siRNA therapies targeting coagulation disorders, cardiometabolic diseases, and obesity.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62131#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62131\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62131#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0105.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/0105.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62131#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases - Insight, China&#039;s Pharmaceutical Industry","description":"Sirius Therapeutics, a clinical-stage biotechnology company founded in 2021, announced it has submitted its listing application to the Hong Kong Stock Exchange for an initial public offering (IPO), advancing its pipeline of siRNA therapies targeting coagulation disorders, cardiometabolic diseases, and obesity.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62131","og_locale":"en_US","og_type":"article","og_title":"Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases","og_description":"Sirius Therapeutics, a clinical-stage biotechnology company founded in 2021, announced it has submitted its listing application to the Hong Kong Stock Exchange for an initial public offering (IPO), advancing its pipeline of siRNA therapies targeting coagulation disorders, cardiometabolic diseases, and obesity.","og_url":"https:\/\/flcube.com\/?p=62131","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-01T15:35:28+00:00","article_modified_time":"2026-04-01T15:35:29+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0105.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62131#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62131"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases","datePublished":"2026-04-01T15:35:28+00:00","dateModified":"2026-04-01T15:35:29+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62131"},"wordCount":442,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=62131#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0105.webp","keywords":["IPO","RNAi \/ ASO","Sirius Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62131#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62131","url":"https:\/\/flcube.com\/?p=62131","name":"Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=62131#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=62131#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0105.webp","datePublished":"2026-04-01T15:35:28+00:00","dateModified":"2026-04-01T15:35:29+00:00","description":"Sirius Therapeutics, a clinical-stage biotechnology company founded in 2021, announced it has submitted its listing application to the Hong Kong Stock Exchange for an initial public offering (IPO), advancing its pipeline of siRNA therapies targeting coagulation disorders, cardiometabolic diseases, and obesity.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62131#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62131"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=62131#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0105.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0105.webp","width":1080,"height":608,"caption":"Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62131#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/0105.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62131","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62131"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62131\/revisions"}],"predecessor-version":[{"id":62134,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62131\/revisions\/62134"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/62133"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62131"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62131"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62131"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}